Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) followed Surgery for locally advanced adenocarcinoma of esophagogastric junction


Clinical Trial Description

The neoadjuvant chemotherapy/chemoradiotherapy with surgery is the standard treatment in NCCN guideline. But many patients refused or abandon radiotherapy because of the intolerable adverse effects. We designed a single-arm, open-label, phase II trial of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) followed by radical surgery for locally advanced adenocarcinoma of esophagogastric junction. The purpose of this study is to observe and evaluate the efficacy and safety. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04813523
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact Hongjing Jiang, MD, PhD
Phone 8618622221069
Email jianghongjing@tmu.edu.cn
Status Recruiting
Phase Phase 2
Start date April 1, 2021
Completion date March 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Active, not recruiting NCT03719833 - Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents
Not yet recruiting NCT05529940 - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Phase 3
Not yet recruiting NCT04384601 - Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer Phase 3
Recruiting NCT04576143 - Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer Phase 2/Phase 3
Not yet recruiting NCT03688035 - Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Recruiting NCT03493880 - The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
Completed NCT06149884 - Micrometastases in Axillary Lymph Nodes in Breast Cancer, Post-neoadjuvant Chemotherapy
Recruiting NCT03750669 - Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer Phase 2
Recruiting NCT03715686 - To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes N/A
Recruiting NCT05522985 - Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT03349177 - Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy Phase 2/Phase 3
Terminated NCT03585062 - Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer Phase 2
Enrolling by invitation NCT06120309 - New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer
Recruiting NCT04004559 - MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)
Recruiting NCT04047693 - Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma Phase 2
Recruiting NCT06220214 - Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer Early Phase 1
Recruiting NCT05910710 - Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Suspended NCT05503108 - Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer Phase 3
Recruiting NCT05367206 - Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial Phase 3